When does guideline production reley on qualitative consideration of cost effectiveness?

T. Wilkinson, J. Hayre, M. Dzingina, S. Ward & G. Rogers
Background: Good practice suggests that, when developing Clinical Guidelines, cost effectiveness (CE) evidence should be considered for each Clinical Review Question (CRQ) where practically possible. The form of CE evidence considered may include de novo cost-utility models and/or the qualitative[for full text, please go to the a.m. URL]